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Abstract.  Affinity-labeling experiments have detected 
hetero-oligomers of the types I, II, and UI transform- 
ing growth factor/3 (TGF-/3) receptors which mediate 
intracellular signaling by TGF-/3, but the oligomeric 
state of the individual receptor types remains un- 
known. Here we use two types of experiments to show 
that a major portion of the receptor types II and HI 
forms homo-oligomers both in the absence and pres- 
ence of TGF-/3. Both experiments used COS-7 cells 
co-transfected with combinations of these receptors 
carrying different epitope tags at their extracellular 
termini. In immunoprecipitation experiments, radiola- 
beled TGF-13 was bound and cross-linked to cells co- 
expressing two differently tagged type II receptors. Se- 
quential immunoprecipitations using anti-epitope 
monoclonal antibodies showed that type II TGF-/3 
receptors form homo-oligomers. In cells co-expressing 
epitope-tagged types II and III receptors, a low level 
of co-precipitation of the ligand-labeled receptors was 
observed, indicating that some hetero-oligomers of the 
types II and III receptors exist in the presence of 
ligand. 
Antibody-mediated cross-linking studies based on 
double-labeling immunofluorescence explored co- 
patching of the receptors at the cell surface on live 
cells. In cells co-expressing two differently tagged type 
II receptors or two differently tagged type III recep- 
tors, forcing one receptor into micropatches by IgG 
induced co-patching of the receptor carrying the other 
tag, labeled by noncross-linking monovalent Fab'. 
These studies showed that homo-oligomers of the 
types II and ~I receptors exist on the cell surface in 
the absence or presence of TGF-/31 or -/32. In cells 
co-expressing types II and 1]/receptors, the amount of 
heterocomplexes at the cell surface was too low to be 
detected in the immunofluorescence co-patching ex- 
periments, confirming that hetero-oligomers of the 
types II and III receptors are minor and probably tran- 
sient species. 
T 
n~ receptors for transforming growth factor/3 (TGF- 
B) ~ regulate  important  cellular  functions,  among 
which are cell proliferation,  differentiation, and motil- 
ity (Roberts and Sporn,  1990; Massagu6,  1990; Moses et 
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1. Abbreviations used in this paper: HA, influenza hemagglutinin; TGF-/3, 
transforming growth factor j3; TGF-/3RI, TGF-/3RII, and TGF-/3RIII, TGF-/3 
receptor  types  I, II and II/, respectively;  DSS, disuccinimidyl  suberate; 
ct-myc, mouse monoclonal antibody which recognizes a specific c-myc se- 
quence; c~-HA, mouse monoclonal antibody which recognizes an epitope 
of the influenza hemagglutinin (HA) protein; FITC-IgG GctRIgG, fluores- 
cein-coupled  goat IgG anti-rabbit  IgG; G~tMIgG, goat IgG anti-mouse 
IgG; Cy3-Fab' G~tMIgG, goat Fab' anti-mouse IgG conjugated to the cya- 
nine dye Cy3.18. 
al., 1990; Lin and Lodish,  1993). Chemical cross-linking to 
nSI-TGF-13 reveals numerous proteins  that bind the ligand 
with high affinity, including cell-surface receptors as well as 
soluble and extracellular matrix proteins (Massagu6,  1992; 
Lin and Lodish,  1993). Among the cell-surface receptors, 
the most widely distributed  are the types I (55 kD), II (80 
kD),  and HI (280  kD) TGF-/3 receptors (Cheifetz  et al., 
1987; Segarini et al., 1989; Massagu6,  1992; Lin and Lod- 
ish,  1993). The TGF-B receptors type I (TGF-/3RI) and type 
II (TGF-/3RID are thought to mediate the multiple effects of 
TGF-/3, while type I~ receptors (TGF-BRIII) are involved in 
presentation of the ligand  to the signaling  receptors (re- 
viewed in Massagu6,  1992; Lin and Lodish,  1993). 
TGF-/3RIII is a transmembrane proteoglycan with a short, 
highly conserved, cytoplasmic domain that has no apparent 
signaling motif (Wang et al.,  1991; L6pez-Casillas  et al., 
1991; Mor6n et al.,  1992). In most cell types TGF-/3RIII is 
the most abundant TGF-/3 receptor subtype (Segarini et al., 
1989; Massagu6, 1992). TGF-/3RIII and its soluble secreted 
ectodomain (Andres et al., 1989) may act as "reservoir" mol- 
ecules for ligand presentation to or retention from the sig- 
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1989; Massagu6,  1992; Lin and Lodish, 1993). Expression 
of TGF-/3RIII enhances  binding  of TGF-/3 ligands,  particu- 
larly TGF-/32, to TGF-/3RII and thus some regulatory inter- 
actions exist between the types II and HI TGF-/3 receptors 
(L6pez-Casillas  et al.,  1993; Moustakas et al.,  1993). Im- 
munoprecipitation  experiments  provided evidence for cell- 
surface complexes  containing  both types II and HI TGF-fl 
receptors. That the TGF-/3RIII primarily has a modulatory 
role is in accord with its structural  features and is also con- 
sistent with the observation that TGF-/3RIII is absent in sev- 
eral ceils that are responsive to TGF-/3 (Ohta et al.,  1987; 
Segarini  et al.,  1989). 
TGF-/3RII is a transmembrane  serine/threonine kinase (Lin 
et al.,  1992; Wrana  et al.,  1992; Tsuchida et al.,  1993a). 
It belongs to the family of receptor serine/threonine  kinases 
that includes  the mammalian,  Xenopus and Drosophila ac- 
tivin type II receptors (Mathews and Vale, 1991; Attisano et 
al.,  1992; Legerski et al.,  1992; Mathews and Vale, 1992; 
Nishimatsu et al., 1992; Shinozaki et al., 1992; Childs et al., 
1993) and the daf-1 and daf-4 gene products of Caenorhabdi- 
tis elegans. The latter two receptors control development of 
the dauer larva (Georgi et al., 1990); the daf-4 gene product 
can act as a type II receptor for bone morphogenetic protein 
(BMP)  (Estevez  et  al.,  1993).  Recently,  specific  eDNA 
clones were identified  as encoding  type I TGF43 receptors 
(Attisano  et al.,  1993; Bassing  et al.,  1993; Ebner et al., 
1993a,b; Franz~n et al., 1993) and the closely related type I 
activin receptors (Attisano et al., 1993; Ebner et al., 1993b; 
Matsuzaki et al., 1993; Tsuchida et al., 1993b). These inte- 
gral membrane proteins are shorter than the TGF-#RII or ac- 
tivin type II receptors, but possess a serine/threonine  kinase 
domain and share conserved sequences with the type II re- 
ceptors in both their extra- and intracellular  domains.  Thus, 
types II and I receptors belong to homologous branches of 
the receptor serine/threonine  kinase family. Several mem- 
bers of this family with presently unidentified  ligand  spec- 
ificity have recently been reported (He et al., 1993; ten Dijke 
et al.,  1993). 
Studies  using  chemically  mutated  mink lung  epithelial 
cells (Boyd and Massagu6,  1989; Laiho et al.,  1990, 1991) 
and tumor cell lines  (Kirnchi et al.,  1988; Segarini  et al., 
1989; Siepl et al.,  1991; Geiser et al.,  1992) that have lost 
the growth-inhibitory  response to TGF-/3 and concomitantly 
lost cell-surface receptors TGF-13RI, TGF-#RII,  or both, 
have led to the notion that both TGF-/3RI and TGF-/3RII are 
required for TGF-/3-mediated  signaling. Functional  interac- 
tions  between TGF-/3RII and  TGF-/3RI are  suggested  by 
studies showing that TGF-/3RII requires TGF-/3RI for signal- 
ing, while binding  of TGF-/31 to TGF-BRI can be detected 
only when  this  receptor  is  co-expressed with  TGF-~RII 
(Wrana et al.,  1992; Attisano  et al.,  1993; Bassing  et al., 
1993; Ebner et al., 1993a,  b; Franz6n et al., 1993; Inagaki 
et al.,  1993; Wieser et al.,  1993). Moreover,  some hetero- 
meric complexes of the types II and I receptors exist,  since 
some "I'GF-/3RI, affinity  labded with  125I-TGF-/31, can be 
co-imrnunoprecipitated  with TGF-/~RII. 
The  important  implications  of  functional  interactions 
among cell-surface TGF-/3 receptors emphasize the need for 
a thorough investigation of their oligomeric structure,  which 
is still largely unknown. In the current work, we investigated 
the formation  of homo- and hetero-oligomers among TGF- 
/3RtI and TGF-/3RHI at the cell surface under native condi- 
tions. Using cells that were co-transfected with various com- 
binations  of epitope tagged and/or wild-type TGF-/3RII and 
TGF-/3RIII, we performed double-labeling  immunofluores- 
cence  experiments  based  on  the  forced patching  of one 
TGF-/3 receptor and following the distribution  of the other 
co-expressed receptor. Complemented with immunoprecipi- 
tation studies,  our data show that both the TGF-/3RII and 
TGF-/3RIII are present at the cell surface as homo-oligomers 
(possibly dimers in the case of the type II receptors) even 
prior to the addition  of ligand.  Furthermore, we show that 
heteromeric TGF-/3RII/TGF-/3RHI complexes  which form 
following ligand binding involve only a minor fraction of the 
cell-surface receptor population. 
Materials and Methods 
Materials 
TGF-B1 and -/32 were supplied by Celtrix Laboratories (Palo Alto, CA) and 
R & D Systems (Minneapolis, MN), and were radioiodinated as described 
(Wang et al.,  1991; Mitchel et al.,  1992). 9El0 (a-myc) mouse ascites, 
which recognizes a specific c-myc sequence (Evan et ai., 1985), was pur- 
chased from Harvard Monoclonals (Boston, MA). 12CA5 (a-HA) mouse as- 
cites, which recognizes an epitope of the influenza hemagglutinin (HA) pro- 
tein (Wilson et al., 1984), was purchased from BAbCO (Berkeley, CA). ~-IIN 
antibodies, raised in rabbits against a KLH-coupled peptide corresponding to 
the Lys3°-Ala  44 segment of the human TGF-BRH, were those described by us 
earlier and shown to be specific for the TGF-BRII (Moustakas et al., 1993). 
IgG fractions were prepared from the mouse ascites or the rabbit serum by 
ammonium sulfate precipitation followed by DEAE-cellulose chromatogra- 
phy (Harlow and Lane, 1988). F(ab')2 fragments were generated by pepsin 
digestion, following the protocols of Kurkela et al. (1988) for mouse IgG 
or Henis et al. (1985) for rabbit IgG. Fluorophore-labeled  affinity-purified 
antibodies, including fluorescein-coupled goat IgG anti-rabbit  IgG (FITC- 
IgG Gc~RIgG)  or anti-mouse IgG (G~MIgG), and goat F(ab')2 anti-mouse 
IgG conjugated to the cyanine dye Cy3.18 (Biological Detection Systems) 
(Cy3-F[ab']2  Gc~MIgG), were  obtained  from Jackson  Immunoreseareh 
Labs (West Grove, PA). All the F(ab')2 preparations were reduced by mer- 
captoethanol and alkylated with iodoacetamide to generate monovaient Fab' 
fragments (Henis et al., 1985). To eliminate possible traces of IgG, the Fab' 
preparations were treated with protein A-Sepharose (for rabbit or goat IgG) 
or protein G-Sepharose (for mouse IgG). The resulting Fat/were free of 
contamination by F(ab')2 or IgG, as judged by SDS-PAGE  under nonreduc- 
ing conditions. 
Expression Vectors  for Epitope-tagged 
TGF-f3 Receptors 
Epitope tagging was performed according to Kolodziej and Young (1991), 
using site-directed mutagenesis on uracil-containing single-stranded phage- 
raids (Kunkel et ai., 1987). The human TGF-~SRII  eDNA (H2-3FF clone; 
Linet ai., 1992) was inserted into the SV-40 expression vector pcDNA-1 
(Invitrogen, San Diego, CA) via the EcoRI site on the polylinker (Lin et 
ai., 1992). Using this vector, which also carries an MI3 origin of replica- 
tion,  single stranded phagemids were grown in a dut- ung- Escherichia 
coli strain  (CJ236/P3;  Invitrogen) with M13K07 (Bio-Rad Laboratories, 
Cambridge,  MA) as helper phage. Site-directed mutagenesis on this tem- 
plate was performed with mutaganic oligonucleotides (Research Genetics, 
Huntsville, AL) encoding the epitope-tag sequence flanked by the sequences 
corresponding to nucleotides 62-78 (on the 5' end) and 79-94 (3' end) of 
the human TGF-13RII (counting the A of the methionine cedon of the eDNA 
as I; Lin et ai., 1992). The tag sequences used encoded either the influenza 
HA epitope  YPYDVPDYA (recognized by monoclonai antibody  12CAS; 
W'dson et ai., 1984) or the human c-myc epitope EQKLISEEDL (recognized 
by monoclonal antibody 9El0; Evan et ai.,  1985). Each tag was inserted 
in-frame,  nine bases downstream of the putative signal peptide sequence 
(Lin et al., 1992). Double stranded pcDNA-I preparations  with inserts of 
the wild-type TGF-~3RII  or the epitope-tagged receptors  were digested by 
Pstl, cutting each preparation in three places (at the polylinker, at position 
206 in the TGF-~RII eDNA coding sequence, and in the 3' noncoding region 
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eeptor encoding most of the coding region of the eDNA was ligated with 
the 4.2-kb piece from a preparation containing HA- or c-myc-tagged  NH2- 
terminal TGF-/3RII sequences and the cloning vector pcDNA-I.  The result- 
ing constructs contained as insert all of the TGF-/3RII coding region, most 
of which was derived from the wild-type,  untagged receptor clone, and the 
NH2-terminal  t~,ion (including the tag) derived from the tagged receptor 
clone. The coding regions derived from the tagged cDNAs (nucleotides 
1-206 in the TGF-~RII sequence; Lin et al.,  1992) were verified by DNA 
sequencing. 
The rat TGF-/3RIII eDNA (R3-OFF clone; Wang et al.,  1991) was in- 
serted into the SV-40 expression vector pcDNA-I/neo 0nvitrogen) via the 
Hind HI polylinker site.  Mutagenesis was carried out as described above 
for TGF-/3RII, except that the epitope-tag sequences were flanked by se- 
quences corresponding to nueleotides 61-75 (on the 5' end) and 76-90 (3' 
end) of the rat TGF-/~Rm eDNA sequence (counting the A of the methio- 
nine codon of the eDNA as 1, Wang et al.,  1991). This yielded in-frame 
insertions of the HA or c-myc epitope-tags six bases downstream of the 
putative signal peptide sequence  (Wang et al.,  1991). Double-stranded 
preparations of peDNA-l/neo with wild-type,  untagged rat TGF-/SRIII or 
with epitope-tagged  rat TGF-/SRIII inserts were digested by XbaI, which cut 
the plasmids at the polylinker,  and BstEH, which cut at position 255 of the 
cDN.gs  coding sequence.  The 5.5-kb fragment from the wild-type,  un- 
tagged receptor encoding most of the coding region and 3' untranslated se- 
quences of the eDNA was ligated to the 7.6-kb fragment from a preparation 
containing HA- or c-myc-tagged NH2-terminal  TGF-/~RIII sequences  and 
the cloning vector pcDNA-I/neo.  The resulting plasmids contained inserts 
with all of the TGF-/3RIII coding region, most of which was derived from 
the wild-type,  untagged receptor clone but with nucleotides 1-255 originat- 
ing from the tagged receptor cDNAs.  This region was verified for each 
tagged receptor by DNA sequencing. 
In the case of human TGF-/SRIH, a eDNA clone from HepG2 cells, iden- 
tical in sequence to the one cloned by Mor6n et al. (1992), was inserted into 
pcDNA-I/neo via the HindIII and NotI polylinker sites. Site-directed  muta- 
genesis was performed using oligonueleotides  encoding the epitope-tag se- 
quences flanked by the sequences corresponding to nucleotides 672-686 
(on the 5' end) and 687-701  (3' end) of the human TGF-/~RIII sequence 
(counting as 1 the first nucleotide of the published sequence; Mor~n et al., 
1992). The epitope-tags were inserted in-frame at the equivalent position 
to that in the rat type IH receptor (between Pro  22 and Glu  23 in the human 
TGF-/3RIII).  The entire coding regions of the epitope-tagged  TGF-/SRIII 
cDNAs were sequenced, to verify that they included the tags and did not 
contain any other mutations. 
COS-7 Cell Transfections 
COS-7  cells (CRL  1651; American Type Culture Collection, Rockville, 
MD) were grown in DME supplemented with 10% FCS,  100 U/ml penicil- 
lin, and 100 ~tg/ml streptomycin (GIBCO BRL, Gaithersburg, MD). They 
were  transiently transfected by  the  DEAE-dextran method  (Seed  and 
Arutfo,  1987) using pcDNA-I or poDNA-I/neo containing the TGF-BRII or 
m  eDNAs (tagged or untagged).  Immunofluorescence  and ligand binding 
and/or immunoprecipitation assays were performed 44-48 h after trans- 
fection. 
Receptor Cross-linking 
Binding and cross-linking of 100 pM 125I-'I'GF-~l  to cells grown on 6-well 
trays  or  100 nun dishes (Coming Inc., Coming, NY) was as described 
(Moustakas et al.,  1993).  Cross-linked proteins were resolved by 5-10% 
linear gradient SDS-PAGE under reducing conditions and exposed to Kodak 
XAR film at -70°C. 
Receptor Immunoprecipitation 
IgG fractions of 9El0 (a-mye) and 12CA5 (a-HA) monoclonal antibodies 
were described above.  A  rabbit pre-immune serum was  also used as a 
nonspecific control for immunopreeipitations. Cell-surface TGF-/~ recep- 
tors were labeled with 100 pM 1~I-TG~I as described above. 5  ×  106 
cells were dissolved in 1 mi of ice-cold immunopreeipitation 0P) buffer 
(PBS containing 1% Triton-X-100, 1 mM EDTA, and 2 mM phenylmethyl- 
sulfonyl fluoride).  Extracts were precleared by incubation with 50 t~g/nfl 
protein A-Sepbarose (Sigma  Chemical Co.,  St.  Louis, MO) or protein 
G-Sepharose (Pharmaeia LKB).  Then 5-10 pg/ml of the appropriate IgG 
was added and reactions were incubated at 40C for 4-12 h. This was fol- 
lowed by addition of 50 gg/ml protein A-Sepbarose (for a-HA and pre- 
immune serum) or 50/tg/ml protein G-Sepharnse (for a-myc) to precipitate 
the immunocomplexes.  The pellets were thoroughly washed in IP buffer. 
For sequential irnmunoprecipitations of single or double epitope-ta~dged 
receptors, the immunocomplexes  from the first immunoprecipitation reac- 
tions were dissolved in a small amount of a solution containing 1% SDS, 
50 m_M DTT, and 10% ~-mercaptoethanol, boiled for 5 rain, and mixed 
thoroughly. The eluted proteins were diluted in IP buffer such that the final 
SDS concentration was less than 0.1%. Monoclonal IgG's were added at the 
above-noted concentrations, aad reactions were incubated at 4"C for 12 h. 
Finally,  immunocomplexes  were precipitated with protein A- or protein 
G-Sepbarose as above. These secondary immunopellets were thoroughly 
washed with IP buffer, dissolved in I.aemmli loading buffer, and subjected 
to 5-10% linear gradient SDS-PAGE prior to autoradiography. 
Immunofluorescence 
44-48 h after transfecfion,  COS-7 cells were washed twice with serum-free 
DME, and incubated 30 rain at 37"C to allow digestion of serum-free DME, 
and incubated 30 rain at 370C to allow digestion of serum-derived ligands. 
After washing twice with cold I-IBSS (GIBCO BRL) supplemented with 
20 mM Hepes and 1% fatty acid-free BSA (Sigma Chemical Co.) (HBSS/ 
Hepes/BSA,  pH 7.2), the cells were incubated in the same buffer (1 h, 4"C) 
with normal goat IgG (200 t~g/ml) to block nonspeeifie binding. This was 
followed by successive  incubations (45 rain, 4"C, with three washes be- 
tween incubations) with anti-tag or a-I/N Fab' or IgG (alone or in various 
combinations), followed by various combinations of goat anti-rabbit Fab' 
or IgG (unlabeled, or labeled with FITC or with the Cy3 eyanine dye). Cy3, 
whose excitation and emission wavelengths  resemble tetramethyirboda- 
mine, was preferred  over tetramethylrhodamine due to its higher fluores- 
cence yield, especially important in Fab' labeling.  The details of each suc- 
cessive labeling protocol depend on the specific experiment and are given 
in the figure  legends.  The samples were washed three times with cold 
HBSS/Hepes,  fixed successively  in methanol (-200C, 5 rain) and acetone 
(-20"C, 2 rain), and mounted with Slowfade (Molecular Probes, Eugene, 
OR) mounting solution. Fluorescence micrographs were taken using rhode- 
mine (for Cy3 fluorescence) or FITC (with a narrow band-pass filter) condi- 
tions with a 63 x  objective, immersed in oil, on a Zeiss Axiophot fluores- 
cence microscope. 
Results 
To date, only heteromeric  complexes of the types I and II, 
and the types II and m, TGF-fl receptors have been detected. 
In these studies, radiolabeled TGF-/~ was bound and cross- 
linked to cell-surface receptors, followed by detergent solu- 
bilization, immunoprecipitation with an antireceptor anti- 
body, and gel electrophoresis. While this approach is highly 
sensitive and can detect low levels of  heterocomplexes (Wrana 
et al.,  1992;  Inagaki, et al.,  1993;  L6pez-Casillas et al., 
1993;  Moustakas et al.,  1993),  it is not applicable to the 
study of homo-oligomers due to the inability to distinguish 
between identical subunits. Furthermore, detergent solubili- 
zation is potentially disruptive for certain noncovalent pro- 
tein complexes. 
To develop a system and method capable of detecting both 
homo- and hetero-oligomeric complexes containing TGF- 
/3RII  and  TGF-BRIII  under  native  conditions,  we  have 
tagged each receptor with two different epitopes. The epi- 
tope tags were introduced at the NH: termini of the extra- 
cellular domains, to enable double-labeling immunofluores- 
cence studies on live cells (Henls et al.,  1990)  as well as 
immunoprecipitation studies on affinity-labeled receptors. 
These types of experiments are performed best at a high re- 
ceptor density at the cell surface, particularly because this 
enables good visualization by immunofluorescence. For this 
reason, transient expression in COS-'/cells was chosen. The 
human TGF-/3RII eDNA (Lin et al., 1992) in the SV-40 ex- 
pression vector pcDNA-I was modified such that either a 
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9El0 (Evan et al., 1985),  or the HA epitope, recognized by 
the monoclonal antibody 12CA5 (Wilson et al.,  1984),  was 
inserted three amino acids downstream of the putative site 
of signal peptidase cleavage (the epitope tags are located be- 
tween Pro  26 and His27). In the case of TGF-/3RIII,  both the 
rat  (Wang  et al.,  1991) and human (Mor6n et al.,  1992) 
cDNAs in the expression vector peDNA-I/neo were modi- 
fied to include either of the c-myc or HA epitope tags. The 
tags were inserted two amino acids downstream of the puta- 
tive site of signal peptidase cleavage in the rat sequence (be- 
tween Pro  25 and Glu  26) or in the equivalent position in the 
human  TGF-/3RIII  sequence  (between  pro2:  and  Glu23). 
When transiently expressed in COS-7 cells using the SV-40 
vectors, the tagged receptors were synthesized, delivered to 
the cell surface, and bound ligand indistinguishably from the 
wild-type receptors (Fig. 1 A; and data not shown). The in- 
sertion of the epitope tag in these specific locations does not 
interrupt the biological activities of the receptors, as shown 
for HA-tagged "I'GF-/3RII  in a growth-inhibition assay (Wrana 
Figure L Affinity  labeling of wild-type and epitope-tagged types II 
and III TGF-/3  receptors. Specificity  of  anti-epitope immunoprecip- 
itation and co-immunoprecipitation  of receptor type II with III. (A) 
COS-7 cells were transiently transfected  with human TGF-/3RII,  ei- 
ther wild-type (lanes 2, 5, and 8, labeled 2), c-myc-tagged (lanes 
3, 6, and 9, 2M), or HA-tagged (lanes 4,  7, and 10, 2a), or with 
wild-type (lane 11, 3), c-myc-tagged (lane 12, 3M), or HA-tagged 
(lane 13, 3  H) rat TGF-/~RIH. Cells were incubated with 100 pM of 
t:5I-TGF-/~I and bound ligand was cross-linked to cell-surface 
receptors. Detergent extracts of the transfected  cells were analyzed 
directly by 5-10% SDS-PAGE (lanes 2-4 and 11-13, total) or after 
immunoprecipitation  with the anti-myc  antibody (lanes 5-7, c~-myc) 
or with the anti-HA antibody (lanes 8-10, c~-HA). Molecular weight 
markers are in lane 1 and their positions are indicated on the left 
margin. The positions of the types HI and II receptors and cross- 
linked dimeric TGF-/3 are noted on the right margin. (B) COS-7 
cells were transfected  with combinations  of  wild-type  or HA-tagged 
receptors, affinity  labeled with 100 pM of 125I-TGF-/~l,  and immu- 
noprecipitated with the c~-HA mAb. Lane 1, HA-tagged rat TGF- 
/3RIII; lane 2,  HA-tagged human TGF-/~RI/ plus wild-type rat 
TGF-/3RIII; lane 3, wild-type human TGF-/3RII  plus HA-tagged  rat 
TGF-/3RIII; lane 4, HA-tagged human TGF-/3RII  plus HA-tagged 
rat TGF-/3RIII; lane 5, wild-type human TGF-/3RIII; lane 6, HA- 
tagged human TGF-/3RII  plus wild-type human TGF-/3RIII.  Molec- 
ular weight markers are in lane 7 and their positions are indicated 
on the right margin. The positions of the types HI and II receptors 
are marked on the left margin. 
et al., 1992) and the c-myc-TGF-f3RIII in an assay based on 
modulation of the growth-inhibitory response to  TGF-/32 
(L6pez-Casillas et al.,  1993). 
Co-imraunoprecipitation  Studies Identify 
A~inity-labeled TGF-[3RH Homo-Oligomers and 
TGF-{3RII-TGF-[3RIII  Hetero-Oligomers 
125I-TGF-/~I was  bound  and  cross-linked  to  COS-7  cells 
transfected with various combinations of epitope-tagged or 
-untagged TGF-BRII (human) and TGF-BRIII (rat or hu- 
man). Immunoprecipitation on singly transfected cells using 
a-HA or ot-myc IgG showed that these antibodies precipitate 
only the type II receptors carrying the appropriate epitope 
tag (Fig. 1 A, lanes 6and 10, and B, lane 1), but not untagged 
receptors or receptors carrying the other tag (Fig. 1 A, lanes 
5,  7, 8 and 9, and B, lane 5). The same specificity applied 
to the epitope-tagged type III receptors (Fig. 1 B; and data 
not shown), the only complication being that the ot-myc IgG 
cross-reacted weakly with afffinity-labeled HA-tagged type 
HI receptors (Moustakas, A., data not shown). This limited 
our  analysis of the  type III  receptors  using  the  affinity- 
labeling/immunoprecipitation approach and only the appro- 
priate, noncross-reacting combinations of type HI receptors 
were further tested. 
The endogenous TGF-/3 receptors in COS-7 cells were not 
detectable under the conditions of our binding and cross- 
linking assay (not shown). Transfection with the eDNA en- 
coding the human TGF-BRII resulted in specific binding and 
cross-linking of TGF-/3 to this receptor only (Fig. 1 A, lanes 
2-4) and no type I TGF-/3 receptors co-immunoprecipitated 
with the type II receptors (Fig. I A, lanes 5-10). Transfeetion 
with cDNAs encoding the rat (Fig. 1 A, lanes 11-13, and B, 
lanes 1-4 and 6) or human (not shown) TGF-BRIII resulted 
in specific binding and cross-linking of TGF-B to the type III 
receptor as well as to two additional, closely migrating TGF- 
B-binding proteins of ,~45-52 kD. We have consistently ob- 
served these low molecular weight binding proteins in this 
and other cell systems where the type III receptor is overex- 
pressed (Inagaki et al.,  1993).  These affinity-labeled pro- 
teins co-precipitate with antibodies specific for the type HI 
receptor (Moustakas et al.,  1993) or with the monoclonal 
antibodies specific for the appropriate  epitope tags used, 
even under denaturing conditions, suggesting that these spe- 
cies are antigenlcally related to the type III receptor. These 
proteins are distinct from the TGF-B type I receptor since in 
this gel system the type I receptor co-migrates exactly with 
the 69-kD molecular weight marker whereas the doublet mi- 
grates faster.  Further, neither of the affinity-labeled doublet 
proteins is precipitated by antibodies specific for the TGF- 
~RI (Moustakas, A., unpublished results). Nor do these two 
proteins exhibit the characteristic sensitivity of the TGF-/3RI 
to pretreatment of ceils with DTT (Inagaki et al., 1993) and, 
unlike  affinity-labeled type  I  receptor,  they  do  not  co- 
immunoprecipitate with the type II receptor. These two pro- 
teins most probably represent membrane bound forms of the 
type III receptor whose exact molecular nature remains un- 
known. 
In cells cotransfected with TGF-/3RII and TGF-/~RIII and 
labeled with  I:5I-TGF-~I, immunoprecipitation of one  re- 
ceptor type, carrying a specific epitope tag, was accompa- 
nied by detectable co-precipitation of  the other receptor type 
(either untagged or carrying the other tag) (Fig.  1 B, lanes 
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was also detected when TGF-~RII (tagged or untagged) was 
precipitated using a rabbit polyclonal anti-peptide antibody 
directed against an NH2-terminal epitope (Lys  3° to Ala  .4) of 
the human TGF-/3RII (a-l/N; Moustakas et al.,  1993;  and 
data not shown). Co-precipitation of affinity-labeled TGF- 
/3RI/was detected when TGF-/3RHI (tagged or untagged) 
was precipitated using a rabbit polyelonal anti-peptide anti- 
body directed against an exoplasmic domain epitope (Gly  ~ 
to  Tyr  s2°) of the rat  TGF-BRHI (Moustakas,  A.,  unpub- 
lished results). These findings are in accord with recent ob- 
servations  on  co-immunoprecipitation  of  TGF-BRII  and 
TGF-BRIII in several cell types (I.xSpez-Casillas  et al., 1993; 
Moustakas et al.,  1993).  Addition of any of the above anti- 
bodies, at the concentrations used in the immunoprecipita- 
tion or immunofluorescence  experiments, during the incuba- 
tion  with  t25I-TGF-/31 did  not  affect  ligand  binding  or 
cross-linking, indicating that these antibodies do not inhibit 
TGF-B1 binding to either receptor (not shown). 
Formation of homo-oligomeric complexes among a single 
type of TGF-/3 receptor was not studied previously. In order 
to examine the formation of such complexes, sequential im- 
munoprecipitation  experiments  were  performed  on  cells 
coexpressing HA- and c-myc-tagged type II receptors. Fig. 
2 shows that these receptors, affinity labeled with Iz*I-TGF- 
/31, can be co-immunoprecipitated demonstrating that homo- 
oligomers of the type 11 receptor exist on the cell surface, at 
least in the presence of ligand. In the key samples (Fig. 2 B, 
lanes 7 and 8) cell extracts were immunoprecipitated with 
one monoclonal anti-epitope antibody, the immunoprecipi- 
tates were boiled in a solution containing SDS, and eluted 
polypeptides  were  then  re-immunoprecipitated  with  the 
other monoclonal antibody. The c-myc-tagged type II recep- 
tor cross-linked to TGF-BI can be co-immunoprecipitated  by 
the o~-HA monoclonal antibody (Fig. 2 B, lane 7). It is not 
co-immunoprecipitated if the cells do not express the HA- 
tagged receptor (Fig. 2 A, lane 5), nor if a preimmune serum 
is used for the first immunoprecipitation (B, lane 5). Simi- 
larly, HA-tagged type II receptor cross-linked to TGF-B1 can 
be co-immunoprecipitated with the o~-myc  monoclonal anti- 
body (Fig. 2 B, lane 8). It is not co-immunoprecipitated if 
the cells do not express the c-myc-tagged receptor (Fig. 2 
A,  lane 10)  or if the first immunoprecipitation is  with a 
preimmune serum (B, lane 6).  Thus, affinity-labeled HA- 
and c-myc-tagged type II receptors are in mutual complexes 
on the cell surface. 
We were unable to demonstrate co-immunoprecipitation 
of HA- and c-myc-tagged type HI receptors using a similar 
protocol. Since the immunofluorescence copatching experi- 
ments (see below) demonstrate that type HI homo-oligomers 
do exist, one explanation for this discrepancy is that homo- 
oligomeric type HI complexes do not withstand detergent 
solubilization and thus are not detected by the immunopre- 
cipitation protocol. A second is that, while primary immu- 
noprecipitation of epitope-tagged TGF-BRIII after binding 
cross-linking was very efficient (Fig. 1 B), the efficiency of 
the secondary immunoprecipitation of the denatured type HI 
receptor (after boiling in SDS) is low. 
The immunoprecipitation studies (or any other biochemi- 
cal assay) cannot quantify the fraction of the receptors that 
participate in homomeric complexes, since only a subpopu- 
lation of the cells coexpress the two cotransfected receptors. 
Figure 2. Co-immunoprecipitation  of afffinity-labeled  type II recep- 
tors:  type II receptors form homo-oligomers in the presence of 
TGF-/31. COS-7 cells  were transiently transfected with  c-myc- 
tagged type II receptors alone (.4, lanes 2-7), HA-tagged type II 
receptors alone (,4, lanes 8-13), or both epitope-tagged receptors 
together (B, lane 2-13). Cells were affinity labeled with I00 pM 
I~I-TGF-~I. The total extracts (T, A, lanes 2, 7, 8, and 13, and B, 
lanes 2, 9, and 13) were analyzed by 5--10% SDS-PAGE. Cells were 
solubilized in detergents and  subjected to immunoprecipitation 
with the antibody listed in the numerator: a-myc (M; A, lanes 3, 
4, 9, and 10; B, lanes 3, 8, and 10); cx-HA (H; A, lanes 5, 6, 11, 
and 12; B, 4, 7, and 11) or a control rabbit pre-immtme serum (P; 
B, lanes 5, 6, and 12). As detailed in Materials and Methods, the 
immunoprecipitates were dissolved by boiling in SDS, and sub- 
jetted to immunopreeipitation using the  antibody listed in the 
denominator: ~x-myc  (M; A, lanes 3, 5, 9, and 11; B, 3, 5, and 7); 
cx-HA (H; A, lanes 4, 6, 10, and 12; B, 4, 6, and 8); or the control 
pre-immune serum (P; B, lanes 10, 11, and 12). Immunoprecipi- 
tates were analyzed  by 5-10% SDS-PAGE. Molecular weight  mark- 
ers are in lanes I and 14 and are indicated on the left margin of each 
panel. The position of the type II receptor is marked on the right 
margins. Only the relevant  portions of  the autoradiograms are indi- 
cated. Autoradiography  was performed at -70"C with an intensify- 
ing screen for 3 d (A) or 7 d (B). 
Furthermore,  the  sequential  immunoprecipitation experi- 
ments examine only a small percentage of the cell-surface 
receptor population, due to the low efficiency of chemically 
cross-linking the labeled ligand to the receptors. In addition, 
heterocomplexes containing both  types II  and HI TGF-/3 
receptors may be preferentially labeled in such studies, since 
their formation appears to be mediated by the TGF-/3 ligand. 
Therefore, although they are highly sensitive, the immuno- 
precipitation  studies  cannot determine whether the com- 
plexes represent a major or a minor fraction of the cell-sur- 
face receptors. In spite of  these limitations, it is apparent that 
the  fraction  of TGF-/3RHI  that  coprecipitates  with  HA- 
tagged TGF-/~RII is much smaller than the fraction of c-myc- 
tagged TGF-/~RII that coprecipitates with HA-tagged TGF- 
/3RII (compare Fig. 1 B, lanes I  and 2 with Fig. 2 B, lanes 
4 and 7). To further explore these questions, we restored to 
cell-surface immunofluorescence studies. 
Epitope-tagged Receptors Can be Patched 
on the Surface of Liring Cells 
Immunofluorescence copatching experiments, designed to 
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based on IgG-mediated patching of one polypeptide chain. 
The copatching of another chain (carrying a different epi- 
tope), labeled exclusively with noncross-linking monovalent 
Fab' fragments,  is then followed. These experiments have 
several advantages: (a) they examine the bulk of the cell-sur- 
face receptors; (b) the use of microscopy enables one to se- 
lect exclusively the coexpressing cells for analysis; (c) sensi- 
tivity of  receptor complexes to detergents, as may be the case 
for type HI receptor homo-oligomers, does not present a 
problem as there is no detergent-solubilization step; and (d) 
receptor interactions can be measured in the absence or 
presence of ligand using the same analytical techniques, un- 
like biochemical experiments where the method of analysis 
varies depending on the presence or absence of ligand. 
Surface labeling of live COS-7  ceils  (performed in the 
cold, to avoid internalization) expressing tagged or untagged 
TGF-flRII  or  TGF-~RIII  with  fluorescent  antibodies  is 
shown in Fig. 3, which also depicts controls for the labeling 
specificity. For both TGF-BRII and TGF-BRIII, labeling with 
noncross-linldng monovalent, Fab' fragments resulted in a 
diffuse fluorescent pattern (Fig. 3, A and C). In contrast, la- 
beling with bivalent primary and secondary IgG's led to the 
formation of conspicuous micropatches, presumably due to 
IgG-mediated cross-linking (Fig. 3, B, D, and E). This shift 
indicates that the receptors are laterally mobile at the cell sur- 
face; otherwise they would not be incorporated into patches. 
This situation is ideal for copatching experiments, since it is 
relatively, easy to follow the shift of the Fab'-labeled recep- 
tors from a homogeneous to a patchy distribution. It should 
be noted that the ot-IIN rabbit IgG was more effective in in- 
ducing patching than or-HA or a-myc, probably due to its 
polyclonal nature (Fig. 3, compare B and E). TGF-BRIII un- 
derwent IgG-mediated patching less readily than TGF-/~RII 
(Fig.  3,  compare B  and D),  for which reason patching of 
TGF-BRII was preferred whenever possible. Fig. 3 (F-H) are 
controls for the specificity of the antibodies used. 
The Majority of ~ypes H and III Receptors Are Not 
in Hetero-Oligomers 
Experiments showing the lack of copatching of TGF-BRIII 
with TGF-~RII in the absence of ligand are depicted in Fig. 
4.  These experiments employed COS-7 cells cotransfected 
with TGF-BRII (tagged or untagged) and TGF-/~RIH carry- 
ing another epitope-tag. About 40 % of the positive cells ex- 
pressed both receptor types, and these cells were examined 
for copatching. As shown in Fig. 4, the TGF-BRII patches 
mediated by FITC-IgG (A and E, green) do not overlap with 
the red fluorescence of  the epitope-tagged TGF-BRIII, moni- 
tored by Cy3-Fab' (B and F). In the double-exposure photo- 
graphs  (Fig.  4,  C,  D,  and  G) the TGF-BRII patches are 
green, while the Cy3 fluorescence appears as orange, due to 
the  green FITC background.  Most of the  epitope-tagged 
TGF-/~RIII is smoothly distributed on the cell surface; only 
occasional FITC- and Cy3-1abeled patches coincided, giving 
rise to a yellow color upon double exposure (Fig. 4, lower 
part of G). Qualitatively similar results (not shown) were ob- 
tained  when epitope-tagged TGF-/3RIII was  induced into 
micropatches by appropriate IgG's and epitope-tagged TGF- 
/~RII was  labeled  with  monovalent Fab'.  Importantly,  no 
significant copatching of TGF-BRIII with TGF-/~RII was ob- 
served even on double-labeled cells that expressed low levels 
(just above the limit of detection needed for fluorescence mi- 
croscopy) of one or both receptors. These results indicate 
that only a small fraction-below the level that can be unam- 
biguously detected in the ilnmunofluorescence copatching 
experiments- of the type HI receptors may reside in mutual 
complexes with TGF-/~RII in live cells and in the absence of 
ligand. The lack of copatching is not due to incompatibility 
between human type II and rat type III TGF-/~ receptors, as 
evidenced by the failure of epitope-tagged human TGF-/~RIII 
to copatch with human TGF-BRII (Fig. 4 D). 
In view of the findings of co-immunoprecipitation of the 
types II and III receptors following TGF-/~ binding (see Fig. 
Figure 3. Expression of wild-type and epitope-tagged types II and III TGF-B  receptors on the surface of  transfected COS cells, and patching 
by bivalent but not monovalent antibodies specific for the NH2 termini. COS-7 cells were transfected with the types II or III TGF-B recep- 
tors, untagged or tagged at the NH2 terminus with the HA or c-myc epitope, in the vectors PeDNA-I or peDNA-I/neo. 44 to 48 h after 
transfection the intact cells were labeled at 4°C, in order to label exclusively the cell surface, with the appropriate monovalent FalY or 
IgG. The cells were then washed and labeled with a fluorescent secondary Fab' or IgG, depending on whether or not IgG-mediated patching 
was desired. The results shown for TGF-BRIII were obtained with the rat clone; similar results (not shown) were obtained for the human 
receptor clone. Bar, 20 #m. (A) Cells transfected with the human type II receptor carrying the c-myc epitope at the NH2 terminus (c-myc- 
TGF-BRID were labeled with 50 #g/ml FalY derived from the c~-myc  monoclonal antibody followed by 20/~g/ml Cy3-tagged FalY goat 
anti-mouse antibody (Cy3-FalY  Gc~MIgG). Cell surface tagged type 1I receptors are uniformly distributed. (B) Cells transfected as in A 
were labeled with 20 #g/ml intact IgG ~x-myc  followed by 20 #g/ml FITC-tagged intact goat anti-mouse  IgG (FITC-IgG Gc~MIgG). 
Cell-surface tagged type H receptors are aggregated into small patches. (C) Cells transfected with the rat type HI receptor carrying the 
HA epitope at the NHz-terminus (HA-TGF-/3RIID  were labeled with 50 ftg/ml FalY  derived from the cx-HA  monoclonal antibody followed 
by 20/xg/ml Cy3-FalY  Gc~MIgG. Cell-surface tagged type HI receptors are uniformly distributed on the cell surface. (D) Cells transfected 
as in C were labeled with 20 #g/ml intact c~-HA IgG followed by 20/xg/ml FITC-IgG Gc~MIgG. Many of the cell-surface  tagged type 
HI receptors are aggregated into small patches. (E) Cells were transfected with the wild-type (untagged) TGF-BRII, and labeled with 150 
#g/ml of intact IgG purified from a rabbit antipeptide antibody raised against an NH2-terminal peptide of the type II receptor (a-Ha IgG) 
followed by 30 #g/ml of FITC-labeled goat anti-rabbit IgG (FITC-IgG Gc~RIgG). The cell surface type II receptors are aggregated into 
small patches. (F) Cells transfected with the wild-type (untagged) rat type HI receptor were labeled with 150 #g]ml of intact c~-HN IgG 
followed by 30 #g/ml FITC-GczRIgG.  No surface labeling is evident on any cells. (G) Cells transfected with c-myc-TGF-fJRII were labeled 
with 20 #g/ml intact c~-HA  IgG followed  by 20 #g/ml FITC-IgG Gc~MIgG. No surface labeling is evident on any cells. Similarly, no surface 
labeling was obtained using cells transfected with untagged TGF-BRII or TGF-BRIII. (H) Cells transfected with rat HA-TGF-/~RIII  were 
labeled with 20 #g/ml intact c~-myc  IgG, followed  by 20 #g/ml FITC-IgG Gc~MIgG. No surface labeling is evident on any cells. Similarly, 
no surface labeling was obtained using cells transfected with untagged TGF-BRII or TGF-BRIII. 
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fects of TGF-/31  and TGF-B2 on copatching of the types II 
and HI receptors. The results (Fig. 5) clearly show that even 
in the presence of these ligands, IgG-mediated patching of 
human TGF-flRII (A and E) does not lead to appreciable 
copatching of epitope-tagged rat or human TGF-flRIII (B 
and F). The nonoverlap of the fluorescence is evident in the 
double exposures in Fig.  5,  C and G. The lighter shade of 
green in Fig.  5 A is due to a longer exposure time than in 
E and not due to leakage of Cy3 fluorescence; such leakage 
is negligible as evidenced by the control experiment in H and 
I of Fig. 4. Even addition of disuccinimidyl suberate (DSS) 
after ligand binding, to cross-link some ligand to its recep- 
tor,  prior to the  IgG-mediated patching  did  not result  in 
distinctive  copatching  (Fig.  5,  D  and  H).  The  same  re- 
suits- absence of copatching of the types III and II recep- 
tors-were obtained at several concentrations of TGF-/31 or 
TGF-fl2 (50 pM, 200 pM, 1 nM; data not shown), excluding 
the possibility that sub- or over-saturation of the receptors 
by the ligand interfered with its ability to induce heterocom- 
plexes.  Analogous observations-absence of copatching of 
the  types IN and II receptors-were made when epitope- 
tagged TGF-~RIII  was induced to patch instead of TGF-/3RII 
(not shown). It should be noted that the antibodies used in 
these studies did not affect binding of TGF-~ to its receptors, 
as evidenced by the absence of effects of these antibodies on 
affinity labeling by 1~SI-TGF-fll of the types II or III recep- 
tors expressed in transfected COS cells (not shown).  Simi- 
larly, the presence of concentrations of TGF-/31 or TGF-/32 
up to 1 nM (the highest tested) had no effect on labeling by 
the fluorescent antibodies (Fig.  5). Thus, even in the pres- 
ence of ligand, the level of type II/type III TGF-fl receptor 
heterocomplexes must be low. We conclude that only a minor 
fraction of the  cell-surface TGF-flRII and  TGF-BRIII are 
localized in heteromeric complexes. 
TGF-[3RH and TGF-[3RIII Exist As Homo-Oligomers 
on the Plasma Membrane 
The experiment in Fig. 6 shows that HA- and c-myc-tagged 
type II TGF-~ receptors copatch together on the cell surface 
in the absence (A-C) or presence (D-F) of TGF-~ or TGF- 
fl2.  COS-7 cells were cotransfected with c-myc- and HA- 
tagged TGF-flRII. The receptors carrying one epitope tag 
were forced into patches using primary IgG and FITC-IgG 
secondary antibodies (Fig. 6, A and D) while the receptors 
carrying the other tag were labeled with monovalent Fab' and 
secondary Cy3-Fab' (B and E). As is apparent in the double 
exposures (Fig. 6,  C and F), a very high percentage of the 
cell-surface receptors copatch. There are many coincident 
green and red patches that become yellow upon double ex- 
posure (e.g., Fig. 6, long arrows). Copatching was observed 
in the absence of ligand (Fig. 6, A-C) and was not enhanced 
significantly by the addition of 50 pM to 1 nM TGF-/31 or 
TGF-fl2 ligand (D-F; and data not shown). Similar distribu- 
tions were observed on individual cells expressing high or 
low levels of the receptors (not shown). Addition of DSS af- 
ter ligand binding, to cross-link some ligand to its receptor, 
prior to the  IgG-mediated patching,  did  not  result  in  in- 
creased copatching (data not shown). Interestingly, not all of 
the green FITC-IgG patches coincided with red  Cy3-Fab' 
patches of receptor carrying the other tag (e.g., Fig. 6, short 
arrows). Such a phenomenon is expected in the case of small 
homo-oligomers (dimers or trimers), where the probability 
is high that some homo-oligomers will consist entirely of 
receptor polypeptides bearing the same epitope tag and that 
Figure 4. Types HI and II "I'GF-/$  receptors do not copatch in the absence of ligand. Transfection and live cell immunofluorescence were 
as described under Materials and Methods. (A-C) COS-'/ceils were cotransfeeted with rat HA-TGF-~RIII and wild-type (untagged) human 
type II receptor. 44 h after transfection the intact ceils were labeled at 4°C by the following consecutive steps: (a) 50/zg/ml Fab' fragments 
derived from the mouse anti-HA monoclonal antibody (a-HA Fab') together with 150 #g/ml intact rabbit ct-IIN IgG, (b) 30 #g/ml FITC-IgG 
GaRIgG (to patch the type II receptor) together with 20 #g/ml Cy3-Fab' Gc~MIgG (to label the type 1II receptor).  (A) The fluorescein 
image shows the patches of (untagged) type II TGF-/3 receptors induced by the anti-peptide IgG's. (B) The Cy3 image shows that the HA- 
tagged type III TGF-/3 receptors are uniformly distributed on the cell surface. (C) A double exposure of the fluoroscein and Cy3 images 
shows that most of the patches are green and contain  only patched type II receptors.  The reddish-orange color (red, becoming orange 
upon double exposure due to the contribution of green background by the photography under FITC conditions) is from the Cy3-tagged 
type 131 receptors  and clearly does not overlap with the type lI receptors.  Identical results (not shown) were obtained using c-myc- or 
HA-tagged TGF-/3RII, or c-myc-TGF-f3RIII. (D) A double exposure of the fluorescein and Cy3 images from a cell from an experiment 
similar to that in C, except that transfection was with an HA-tagged human type HI receptor together with wild-type (untagged) human 
type 1I receptor.  As in C, most of the patches are green and contain  only patched type II receptors.  The reddish-orange  color is from 
the Cy3-tagged type HI receptors and clearly does not overlap with the type II receptors.  Similar results (not shown) were obtained using 
epit0pe-tagged  TGF-/~RII or the human c-myc-TGF-~RIII. (E-G) COS-7 cells were cotransfected with rat HA-TGF-flRIII and human 
c-myc-TGF-f3RII. At 44 h the intact cells were labeled at 4°C by the following consecutive steps: (a) 50 #g/ml a-HA Fab' followed by 
20 #g/ml Cy3-Fab' Gc~MIgG, (b) saturating amounts (200 #g/ml) of unlabeled Fab' fragments of goat anti-mouse IgG (Fab' Gc~MIgG); 
this ensures saturation of the or-HA Fab' by secondary Fab'; (c) 20/~g/ml c~-myc  IgG, followed by 20 #g/ml FITC-IgG GotMIgG. (E) The 
fluorescein image shows the patches of c-myc-tagged type II TGF-/3 receptors induced by the a-myc IgG's. (F) The Cy3 image shows that 
the HA-tagged type III  TGF-/3  receptors are distributed throughout the entire surface, concentrated at the cell periphery and near the nucleus. 
They do not overlap the patches of type II receptors.  (G) A double exposure of the fluorescein and Cy3 images shows that most of the 
patches are green and contain only patched c-myc-tagged  type II receptors. The reddish-orange color is from the Cy3-tagged type III recep- 
tors and clearly does not overlap with the type 1I receptors. Similar results (not shown) were obtained using HA-TGF-/3RII  and c-myc-TGF- 
fiRm. (H and I) Controls showing that the addition of unlabeled Fab' Gc~MIgG  after the Cy3-Fat¢ Gt~MIgG (step b in E-G) is sufficient 
to block subsequent nonspecific binding in step c. The cells were transfected with HA-TGF-flRIII only, and then labeled exactly as in E-G 
above. (H) Cy3-Fab' labeling, illustrating the uniform distribution of the HA-tagged type III TGF-/3 receptors.  (I) Shows the nonspecific 
FITC staining of the same field. Bar, 20/~m. 
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receptor polypeptide (see Discussion). 
Similar  studies  demonstrated  copatching  of  HA-  and 
c-myc-tagged type Ill TGF-15  receptors on the cell surface in 
the absence (Fig. 7, A-C) or presence (D-F) of TGF-/31. In 
this case, virtually all of the green patches of tagged type HI 
TGF-/3 receptors induced by the or-HA IgG's (Fig. 7, A and 
D) contained red fluorescence due to the copatched recep- 
tors bearing the opposite epitope tag (B and E), as can be 
seen in the double exposures, where all of the patches are 
yellow (C and F).  However, the inefficient patching of the 
type HI receptors reduces the  resolution in these experi- 
ments. Similar results (not shown) were obtained using other 
TGF-/51 concentrations (50 pM or 1 nM), replacing TGF-/31 
by TGF-/32, or cross-linking the ligand to the surface recep- 
tors with DSS prior to labeling with antibodies. As in the 
former cases, no significant differences could be noticed be- 
tween cells with high versus low surface expression of the 
receptors. 
Discussion 
TGF-/~  has  a  broad  range  of activities,  controlling  cell 
growth,  differentiation, and extracellular matrix composi- 
tion (Massagu~,  1990; Roberts and Sporn, 1990; Moses et 
al.,  1990;  Lin  and  Lodish,  1993).  These  responses  are 
elicited and modulated via high-affinity cell-surface recep- 
tors, principally the types I, II, and HI receptors. Formation 
of hom&- or hetero-oligomeric receptor complexes may play 
an important role in regulating the multiple intracellular sig- 
nals generated by TGF-/3. Several studies have demonstrated 
functional  and  physical  interactions  among  the  different 
receptor subtypes (Wrana et al., 1992; Inagaki et al., 1993; 
L6pez-Casillas et al.,  1993;  Moustakas et al.,  1993), but 
the  molecular  composition  of putative  receptor  hetero- 
oligomers on the cell surface under native conditions is still 
unknown.  Furthermore,  the  existence of receptor homo- 
oligomers  has  not  been  explored.  Here  we  investigated 
homo- and hetero-oligomer formation among types II and HI 
TGF-/~ receptors using cells co-expressing various combina- 
tions of epitope-tagged types II and Ill receptors. We used 
both antibody-mediated cross-linking and immunofluores- 
cence microscopy on live cells, as well as sequential immu- 
noprecipitation reactions on affinity-labeled cell-surface re- 
ceptors. These studies demonstrated that both TGF-/3RII and 
TGF-/3RIII form homo-oligomers at the cell surface, and that 
type H/type HI receptor heterocomplexes comprise only a 
minor fraction of the population of cell-surface receptors, 
implying that the heterocomplexes may represent transient 
species. 
The immunofluorescence copatching experiments on cells 
coexpressing HA-TGF-/3RII  and c-myc-TGF-f3RII, or HA- 
TGF-{3RIII and c-myc-TGF-13RIII (Figs. 6 and 7), corrobo- 
rated by the results of the sequential immunoprecipitation 
experiments on affinity-labeled TGF-flRII (Fig. 2), clearly 
demonstrate for the first time that both types II and 111 TGF-fl 
receptors form homo-oligomers. These homo-oligomers are 
detected in the intact cell plasma membrane, and exist prior 
to ligand binding. Although our experiments used ceils over- 
expressing the transfected receptors, a situation that might 
increase nonspecific interactions, there are several indica- 
tions that the homo-oligomers are not generated as a result 
of high receptor expression. First, many cell types normally 
express  high  physiological  levels  of the  type  HI  TGF-/3 
receptor-~200,000  per  cell  (Massagu~,  1990)-approx- 
imately that found on transfected COS  cells that express 
moderate levels of the type III receptor. Second, even for the 
type II receptor, which is normally expressed at levels of sev- 
eral thousands per cell, the microscopic nature of the im- 
munofluorescence  copatching experiments enabled examina- 
tion of transfected COS ceils expressing as low as 20,000 
type II receptors per cell. (The amount of TGF-flRII at the 
surface of specific transfected COS-7 cells was evaluated by 
measuring the fluorescence intensity on single cells labeled 
by the  ol-IIN antibody and  a  secondary fluorescent IgG, 
using a photomultiplier tube attached to the microscope. The 
intensity was compared to that obtained using similarly la- 
beled H2-16 cells, an SW480 colon carcinoma cell line sta- 
bly transfected with the human TGF-/3RII [Lin, H. Y., A. 
Moustakas, P. Knaus, R. Wells, Y. I. Henis, and H. F. l.xxi- 
ish, manuscript in preparation]. The TGF-/3RII number at 
the surface of the H2-16 cells [~20,000 receptors/cell] was 
independently measured by binding of 125I-TGF-/31 and by 
binding-cross-linking assays).  Yet the results-co-patching 
Figure 5. TGF-fll and TGF-fl2  do not mediate appreciable copatching of  the types II and HI TGF-/3  receptors. (A-C) Ceils were cotransfected 
with human c-myc-TGF-{3RII  and human HA-TGF-flRIII.  44 h after transfection the ceils were preincubated for 2 h at 4°C with 1 nM 
TGF-/31. The ceils were labeled exactly as in A-C of Fig. 4, except that 1 nM TGF-/31 was added to all of the antibody solutions. (A) 
The fluorescein image shows the patches of c-myc-tagged type II TGF-/3  receptors induced by the anti-peptide IgG's. (B) The Cy3 image 
shows that the HA-tagged type m  TGF-fl receptors are uniformly distributed on the cell surface. (C) A double exposure of the fluorescein 
and Cy3 images shows that most of the patches are green and contain only patched type lI receptors. The reddish-orange color is from 
the Cy3-tagged type III receptors and clearly does not overlap with the type II receptors. Similar results (not shown) were obtained with 
50 or 200 pM TGF-/31, or when patching was mediated by c~-myc  IgG instead of c~-IIN IgG. (D) Double exposure of cells transfected 
and labeled as in A-C, except that prior to labeling with the antibodies TGF-fll was cross-linked to the ceil-surface receptors using DSS. 
(E-G) Cells were cotransfected with human c-myc-'l'GF-flRII  and rat HA-TGF-flRIII.  44 h after transfection that cells were preincubated 
for 2 h at 4°C with 200 pM TGF-fl2. Except for the addition of TGF-ff2 to all antibody solutions, rather than TGF-fll, the experiment 
was otherwise identical to that in A-C. (E) The fluorescein image shows the patches of c-myc-tagged type II TGF-fl receptors induced 
by the anti-peptide IgGs. (F) The Cy3 image shows that the HA-tagged type HI TGF-/3 receptors are uniformly distributed on the cell 
surface. (G) A double exposure of the fluorescein and Cy3 images shows that most of the patches are green and contain only patched 
type II receptors. The reddish-orange color is from the Cy3-tagged type III receptors and clearly does not overlap with the type H receptors. 
Similar results (not shown) were obtained with TGF-/32 at 50 pM or 1 nM, or when patching of the type II receptors was induced by 
c~-myc IgG. (H) Double exposure of ceils transfected and labeled as in E-G, except that prior to labeling with the antibodies TGF-ff2 was 
cross-linked to the cell-surface receptors using DSS. Bar, 20 #m. 
Henis et al. Oligomerization  of TGF-/3 Receptors  149 Figure 6. HA- and c-myc-tagged type II TGF-/~ receptors copatch together on the cell  surface in the absence (A-C) or presence (D-F) 
of TGF-/~I. (A-C) COS-7 cells were cotransfected with HA- and c-myc-tagged type II TGF-/3 receptors. 44 h after transfection  the intact 
ceils were labeled at 4°C by the following consecutive steps: (a) 50 #g/ml t~-myc  Fab' followed by 20 #g/ml Cy3-Fab'  Gt~MIgG, (b) saturating 
amounts (200 #g/ml) of  unlabeled Fab' GctMIgG, and (c) 20/zg/ml ix-HA IgG followed by 20/zg/ml FITC-IgG  Gt~MIgG. (A) The fluorescein 
image shows the patches of HA-tagged type II TGF-/3 receptors induced by the anti-HA IgG and the FITC-IgG GtxMIgG. (B) The Cy3 
image shows that the c-myc-tagged type II TGF-# receptors are also localized in patches.  The long arrow points to examples  of patches 
that contain both HA- and c-myc-tagged type II TGF-/3 receptors, and the short arrow indicates patches that contain only fluorescein-labeled 
HA-tagged type II TGF-/~ receptors. (C) A double exposure of the fluorescein  and Cy3 images shows that many patches  are yellow (e.g., 
long arrow) and contain both HA- and c-myc-tagged type II receptors. Some (short arrow)  are green and contain only fluorescein-labeled 
HA-tagged type II TGF-fl receptors whose patching was induced by the IgG's. (D-F) COS-7 cells  were co-transfected  with HA- and 
c-myc-tagged type II TGF-/~  receptors. 44 h after transfection 200 pM TGF-fl 1 was added and kept in all of  the subsequent labeling solutions. 
After a 2-h preincubation at 4°C the intact cells were labeled at 4°C by the following consecutive steps:  (a) 50 #g/ml c~-HA  Fab' followed 
by 20 #g/ml Cy3-Fab' GctMIgG; (b) saturating  amounts (200/xg/ml) of unlabeled  Fab' GtxMIgG; and (c) 20 #g/ml a-myc IgG followed 
by 20 #g/ml FITC-IgG Gt~MIgG. (D) The fluorescein  image shows the patches of c-myc-tagged type II TGF-/3 receptors induced by the 
ot-myc IgG and secondary FITC-IgG GctMIgG.  (E) The Cy3 image shows that the HA-tagged type II TGF-/3 receptors are also localized 
in patches.  The long arrow points to examples of patches that contain both c-myc- and HA-tagged type II TGF-/3 receptors, and the short 
arrow indicates  patches that contain only fluorescein-labeled  c-myc-tagged type II TGF-/3 receptors. (F) A double exposure of the fluores- 
cein and Cy3 images shows that many patches  are yellow (e.g., long arrow) and contain both c-myc- and HA-tagged type II receptors. 
Some (short  arrow) are green and contain only fluorescein-labeled  c-myc-tagged type 1I TGF-/~ receptors. Similar results (not shown) were 
obtained with 50 pM or 1 nM TGF-/~I, or when TGF-fl2 (same concentrations) was used as the ligand.  Additions  of a DSS cross-linking 
step  after ligand  binding and prior to labeling  with the antibodies  also did not alter the results  (not shown).  Bar,  20 #m. Figure 7. HA- and c-myc-tagged type HI TGF-/3 receptors copatch together on the cell surface  in the absence (A-C) or presence (D-F) 
of TGF-/~I. COS-'/cells were cotransfected with rat HA-TGF-BR/II and rat c-myc-TGF-/~RIII. (A-C) Labeling with antibodies  was exactly 
as in Fig. 6 (A-C). (A) The fluorescein  image shows the patches of HA-tagged type II/TGF-B receptors induced by the anti-HA IgG and 
the secondary  FITC-IgG GctMIgG. (B) The Cy3 image shows that the c-myc-tagged  type 11I TGF-/~ receptors are also localized in patches. 
The long arrow points to examples of patches that contain both HA- and c-myc-tagged type III "I'GF-/3  receptors. (C) A double exposure 
of the fluorescein  and Cy3 images shows that most of the patches  are yellow (e.g., long arrow) and contain both HA- and c-myc-tagged 
type llI receptors. (D-F) Preincubation with 200 pM TGF-/~I and labeling with antibodies was exactly as in Fig. 6 (D--F). (D) The fluores- 
cein image shows the patches of c-myc-tagged type HI TGF-/3 receptors induced by the c~-myc  IgG and the secondary FITC-IgG Gt~MIgG. 
(E) The Cy3 image shows that the HA-tagged type III TGF-/~ receptors are also localized  in patches.  The long arrow points to examples 
of patches that contain both c-myc- and HA-tagged type 111 TGF-/~ receptors. (F) A double exposure of the fluorescein  and Cy3 images 
show that most of the patches are yellow (e.g., long arrow) and contain both c-myc- and HA-tagged type III receptors. Similar results 
were obtained using 50 pM or 1 nM TGF-/~I or TGF-/32, or after adding a DSS cross-linking step prior to labeling  with antibodies  (not 
shown).  Bar,  20 ttm. 
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as in COS cells expressing "~10 times more type II receptor. 
Third, studies on co-immunoprecipitation  of affinity-labeled 
types II and type 111 receptors expressed in transfected COS-7 
ceils gave results  similar  to those obtained using  cells ex- 
pressing normal amounts of the two receptors (L6pez-Casillas 
et al., 1993; Moustakas et al., 1993). Furthermore, the fact 
that no significant amounts of type IFtype 111 heterocomplexes 
were detected by immunofluorescence  copatching  experi- 
ments under identical conditions  (Figs. 4 and 5) implies that 
the copatching  is specific, and that the experimental  condi- 
tions used do not lead to the generation of nonspecific aggre- 
gates of the TGF-B receptors. Our failure to detect homo- 
oligomers of affinity-labeled type l]I receptors by sequential 
immunoprecipitation,  presumably due to the disruption of 
such complexes by the detergent  used to solubilize  the cell 
membranes, also attests to the specificity of formation of the 
observed complexes of the type 1I receptor on the surface of 
COS-7 cells and argues against the notion of induction of re- 
ceptor complex formation by the molecular probes used here. 
Furthermore,  the  same experiments  demonstrate  that  the 
oligomers formed are not simply mediated by the presence 
of the epitope tags or by the anti-tag antibodies,  since other- 
wise they would also mediate the formation  of type H/type 
I~ complexes,  which were not observed in the immunofluo- 
rescence studies. 
The homo-oligomeric state of TGF-/3RIII is in accord with 
the report that the related glycoprotein endoglin  (L6pez- 
Casillas et al., 1991; "Wang et al., 1991) is a disulfide-linked 
homodimer  (Gougos and  Letarte,  1990;  Cheifetz  et  al., 
1992). In the case of the type II receptor, formation of homo- 
oligomers is in agreement with reports that overexpression 
of a truncated kinase-deficient form of the receptor had dom- 
inant negative effects on TGF-/3 signaling (Brand et al., 1993; 
Chen  et  al.,  1993;  Wieser  et  al.,  1993).  These  studies 
prompted the suggestion that the impairment in TGF-/3 sig- 
naling may be mediated by trans inhibition of autophosphor- 
ylation, implying that the receptor can form homo-oligomers. 
Thus, homo-oligomerization  of the type II receptor may en- 
able receptor trans autophosphorylation.  Analogous  find- 
ings were reported for a corresponding kinase-negative  type 
II activin receptor (Hemmati-Brivanlou  and Melton, 1992). 
In view of the evidence for functional interactions between 
TGF-/3RII and TGF-/3RI (Wrana et al., 1992; Inagaki et al., 
1993), it could be argued that type I receptors may stabilize 
the type H receptor oligomers.  However,  the low level of 
TGF-/3RI in the COS-7 cells,  relative  to the overexpressed 
type II and/or type 1II receptors (Fig.  1 A) rules out this pos- 
sibility, and indicates  that  formation  of neither  type II nor 
type HI receptor homo-oligomers require TGF-/3RI. Simi- 
larly,  the type II/type HI receptor heterocomplexes  cannot 
contain stoichiometric amounts of TGF-/3RI, in accord with 
recent reports (L6pez-Casillas  et al.,  1993;  Moustakas et 
al., 1993). It could also be argued that some other native cel- 
lular protein is associated with the observed receptor com- 
plexes and is essential for their formation  (such a possibility 
pertains to any type of co-immunoprecipitation  or copatch- 
ing  experiment,  and therefore also applies  to all previous 
work on TGF-B receptor complexes).  In any case,  such a 
candidate protein(s)  would have to be expressed normally at 
high levels,  and would have to remain associated with the 
types II and HI receptors in the detergent solutions used for 
immunoprecipitation.  Such a candidate protein could not be 
part of the extracellular  matrix or cytoskeleton, since mem- 
brane proteins that stably interact  with these structures are 
laterally  immobile (Edidin,  1987; Jacobson et al.,  1987), 
while the IgG-mediated  shift of TGF-/3RII and TGF-/3RIII 
from a homogeneous to a patchy distribution  demonstrates 
that the majority of these receptors are laterally  mobile. 
In the immunofluorescence  copatching  expe  "rtments dem- 
onstrating TGF-/3RII homo-oligomerization,  a large fraction 
of HA-TGF-/3RII  copatched with c-myc-TGF-~RII, but a sig- 
nificant amount of receptors that did not copatch  was also 
evident (Fig. 6). This is suggestive of small oligomers, prob- 
ably dimers  or trimers.  The reasoning  is as follows: (a) If 
the receptor polypeptides were monomers,  no copatching 
would be seen. (b) If the receptor polypeptides form dimers, 
and then 50% of the receptors would contain polypeptides 
with different epitope tags.  Only such dimers will undergo 
copatching. (c) The fraction of oligomers capable of co-patch- 
ing will increase with the number of subunits in the oligumer 
(75 % for trimers,  87.5  % for tetramers), since the only recep- 
tors that will not copatch are those in which all of the recep- 
tor subunits bear the same epitope tag. Although the copatch- 
ing experiments  are semi-quantitative,  the fraction of green 
FITC-IgG patches that does not coincide with red Cy3-Fab' 
patches is estimated to be between 1/4 and 1/2 (e.g., Fig. 6), 
clearly above the very low level expected for a tetramer or 
a higher-order  oligomer. Thus, if the cell-surface TGF-/3RII 
population is homogeneous, these receptors most likely form 
dimers or tfimers. However, the type II receptor population 
might be heterogeneous with a subpopulation  that does not 
form homo-oligomers and thus  does not copatch.  In this 
case, it is possible that higher order receptor oligomers com- 
prise the fraction that shows copatching. In the immunofluo- 
rescence copatching  experiment  demonstrating  the oligo- 
merit structure of the type rrl receptors (Fig. 7), it was not 
possible to discern non-coincident patches; however, the reso- 
lution  in this particular experiment is lower in view of the 
inherent  low efficiency of the anti-epitope monoclonal anti- 
bodies in inducing  patching  of the type III receptors. It is 
therefore  difficult to draw conclusions concerning  the pos- 
sible size of the TGF-/3RIII homo-oligomers. 
The immunoprecipitation  experiments on cells coexpress- 
ing types II and ITI TGF-/3 receptors demonstrated coprecipi- 
tation of the two receptor types affinity-labeled  by TGF-3 
ligand (Fig. 1 B). These findings are in agreement with simi- 
lar recent studies (L6pez-Casillas  et al., 1993; Moustakas et 
al.,  1993) which detected ligand-induced  TGF-/SRII/TGF- 
/3RII/heterocomplexes. The present study further explores 
these heterocomplexes  by examining the bulk population of 
the receptors at the cell surface-and not only those cross- 
linked to the ligand-using immunofluorescence  copatching 
experiments  (Fig. 4 and 5). These studies  revealed  for the 
first time that the vast majority of the types 1I and HI recep- 
tors do not reside in mutual complexes, even in the presence 
of ligand.  Indeed, a 1:1 stoichiometry is unlikely in view of 
the fact that in most cells TGF-/3RIII is much more abundant 
than  TGF-/3RII (Wang et al.,  1991; L6pez-Casillas  et al., 
1991). The percentage of the types II and 11I receptors resid- 
ing in heterocomplexes  is low-probably below 10%- since 
it cannot be detected in the copatching  experiments.  In any 
case, it must be well below the percentage of type II and type 
III receptors present as homo-oligomers, where copatching 
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Figure 8. Model for interactions between homodimers of the type 
II and type HI TGF-/3 receptors. The two receptors are drawn as 
dimers in the plasma membrane,  in the absence or presence of 
TGF-/3, and are labeled with Roman numerals. TGF-/3  is drawn as 
a filled double ellipse; the type II receptor is drawn with its cyto- 
plasmic kinase domain as an open box; and the type HI receptor 
is drawn with its extracellular glycosaminoglycan chains as dotted 
lines. The heteromeric type II/type HI receptor  complex is depicted 
in the middle  and arrows represent  a possible  route of ligand- 
receptor interactions during initiation of the signal transduction 
pathway. 
could be clearly detected. The presence of  only a minor frac- 
tion of types II and [] receptors in heterocomplexes is con- 
sistent with the proposal that the type I/I receptor enhances 
binding of  TGF-/3 to the type 11 receptors, and that a complex 
comprised of TGF-/3RIII, TGF-/3RII, and ligand is an inter- 
mediate in "presentation" of the TGF-/3 ligand from the type 
[] to the signaling type II and/or type I receptors (Fig. 8; 
L6pez-Casillas et al., 1993). Our results suggest that the ter- 
nary complex of TGF-/3RIII, TGF-/3RII, and TGF-/3 may be 
a  transient  species  in  the plasma  membrane,  one whose 
steady state concentration is always very low. 
Although the type I receptor does not appear to be required 
for the formation of either types II or [] homo-oligomers or 
type H/type [] heterocomplexes, it may interact with some 
of these preformed complexes, and these interactions are 
likely to play a role in signaling by the receptor complex. For 
example, displacement of TGF-/3R[] from an intermediate 
complex, containing the type II and the type [] receptors as 
well as TGF-/3, by TGF-/3RI could represent the pathway for 
formation of a stable signaling complex containing the type 
II and the type I receptors as well as TGF-/3, as proposed by 
L6pez-Casillas et al. (1993), except that the individual recep- 
tors may already be part of a homo-oligomer. That is, what 
were assumed in earlier work to be complexes of TGF-/3 with 
one type II and one type [] (or one type II and one type I) 
receptor could actually be complexes of one TGF-/~ with one 
homodimer of a type II and one homodimer of a type [] re- 
ceptor. Direct association of TGF-flRI with preformed TGF- 
/3RII homo-oligomers is also possible. Further experiments 
on the oligomeric structure of TGF-/3RI and on its interac- 
tions with TGF-~RII and TGF-flRIII are required to address 
these issues. The existence of TGF-fl receptor complexes of 
different compositions offers the potential for a wide reper- 
toire of responses to the same family of ligands, depending 
on the equilibrium between the different receptor complexes. 
These in turn may regulate the multiple intracellular signals 
generated by TGF-/3. 
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